| Autor: |
Durá-Travé, T., Gallinas-Victoriano, F., Moreno-González, P., Urretavizcaya-Martinez, M., Berrade-Zubiri, S., Chueca-Guindulain, M. J. |
| Zdroj: |
Journal of Endocrinological Investigation; 20240101, Issue: Preprints p1-8, 8p |
| Abstrakt: |
Purpose: To analyze whether vitamin D deficiency could condition the growth response to GH therapy, as well as to analyze if GH treatment modifies both seasonal variations and vitamin D levels in these patients. Methods: Retrospective study in 98 prepubertal children with GH deficiency (GHD), aged 4.1–8.9 years treated with GH. Growth rate and blood testing (calcium, phosphorus, IGF-I, 25(0H)D and PTH) were monitored at diagnostic and every six months until 24 months of treatment. A control group was recruited (247 healthy children, aged 3.8–9.7 years). The criteria of the US Endocrine Society were used for the definition of hypovitaminosis D. Results: There were no significant differences in vitamin D deficiency among control (12.5%) and GHD groups (15.3%) before starting treatment. Growth rate and IGF-1 and PTH increased (p< 0.05) during GH treatment, but there were no significant differences in calcium, phosphorus and 25(OH)D. There were no significant differences in growth rate and IGF-1, calcium and phosphorus levels in relation to the seasons along GH treatment. There was no correlation between 25(OH)D and IGF-1 during GH therapy. In every programmed control, patients with vitamin D deficiency showed lower growth rate (p< 0.05) compared to patients with vitamin D insufficiency or sufficiency. Conclusion: GH treatment, at least during the first two years, does not modify the vitamin D levels. Vitamin D deficiency could condition the response to GH therapy so vitamin D monitoring should be considered as part of the routine evaluation of children with GH treatment. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full text from SpringerLink